I read with interest the report by Pronk and colleagues on a dose escalation study of the combination chemotherapy of docetaxel and ifosfamide (Pronk et al, 1998) . They evaluated an alternating sequence of ifosfamide 24-h infusion and docetaxel. Docetaxel preceded 1 h before ifosfamide administration, and in the reverse ifosfamide was followed by docetaxel with a 24-h interval. They described that the maximum tolerated dose (MTD) was higher when docetaxel was administered before ifosfamide than vice versa and that this schedule was recommended for phase II studies.
